Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Baymedica
Deal Size : Inapplicable
Deal Type : Inapplicable
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
Details : delta 9-dominant tetrahydrocannabivarin, d9-THCV is the naturally-occurring variant found in the Cannabis plant, to create unique health and wellness products.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Baymedica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Radicle Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid, tetrahydrocannabinol (“THC”).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Radicle Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Incannex to Acquire APIRx Pharmaceuticals USA, LLC
Details : A focus of the combined APIRx and Incannex group will be the ongoing development of APIRx's CheWell, CanQuit and CanQuit-O cannabinoid combination MCGs to treat cannabis addiction, nicotine addiction and opioid addiction.
Product Name : CheWell
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 24, 2022
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 03, 2014
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabivarin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2011
Lead Product(s) : Cannabidiol,Tetrahydrocannabivarin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin,Cannabidiol
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 08, 2010
Lead Product(s) : Tetrahydrocannabivarin,Cannabidiol
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable